Mark M. Awad, MD, PhD, of Dana-Farber Cancer Institute, discusses phase III findings from the CheckMate 816 trial, which showed a potential clinical benefit to neoadjuvant nivolumab plus ipilimumab vs chemotherapy in patients with resectable non–small cell lung cancer (NSCLC) (Abstract 1261O).
Peter Schmid, MD, PhD, of Queen Mary University of London, discusses phase III findings from the KEYNOTE-522 study, which showed neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab continues to improve event-free survival compared with neoadjuvant chemotherapy alone in patients with early-stage triple-negative breast cancer, regardless of pathologic complete response (Abstract LBA18).
Ze-rui Zhao, PhD, of China’s Sun Yat-sen University Cancer Center, discusses new phase II findings on stereotactic body radiation therapy (SBRT) with sequential immunochemotherapy as a neoadjuvant treatment of patients with resectable non–small cell lung cancer (NSCLC). This therapy yielded a high major pathologic response rate, according to Dr. Zhao (Abstract LBA60).
Jarushka Naidoo, MHS, MBBCh, of the Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, discusses some of the key lung cancer data presented at the ESMO Congress 2023: CheckMate 77T, a phase III study of nivolumab, chemotherapy, and surgery for previously untreated resectable stage II–IIIB NSCLC; the ALINA study of alectinib vs chemotherapy in patients with early-stage ALK-positive NSCLC; and overall survival data from KEYNOTE-671, which established the role of chemoimmunotherapy and pembrolizumab. Dr. Naidoo also reviews data in small cell lung and thymic cancers.
Tina Cascone, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses new phase III findings from the CheckMate 77T trial of patients with previously untreated resectable stage II–IIIB non–small cell lung cancer (NSCLC). The trial showed clinically meaningful improvement in event-free survival with neoadjuvant nivolumab plus chemotherapy followed by surgery and adjuvant nivolumab vs chemotherapy or placebo (Abstract LBA1).
Jonathan D. Spicer, MD, PhD, of McGill University, discusses findings from the KEYNOTE-671 study of perioperative pembrolizumab for patients with resectable early-stage non–small cell lung cancer (NSCLC). Neoadjuvant pembrolizumab plus chemotherapy followed by resection and adjuvant pembrolizumab improved overall survival compared with neoadjuvant chemotherapy and resection alone in stage II, IIIA, or IIIB (N2) disease (Abstract LBA56).
